Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-37148 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CHD5 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- This antibody detects endogenous protein at a molecular weight of 230-250 kDa. Purity is >95% by SDS-PAGE.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 1 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references Large 1p36 Deletions Affecting Arid1a Locus Facilitate Mycn-Driven Oncogenesis in Neuroblastoma.
García-López J, Wallace K, Otero JH, Olsen R, Wang YD, Finkelstein D, Gudenas BL, Rehg JE, Northcott P, Davidoff AM, Freeman KW
Cell reports 2020 Jan 14;30(2):454-464.e5
Cell reports 2020 Jan 14;30(2):454-464.e5
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of CHD5 using CHD5 polyclonal antibody (Product # PA5-37148) at a dilution of 1:500. Lane 1: HEK293T whole cell lysate, Lane 2: NIH-3T3 whole cell lysate, Lane 3: Rat brain tissue lysate.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1. Characterization of 1p36-del-Derived Cell Lines (A) TARGET data from whole-exome and whole-genome sequencing were segregated on the basis of MYCN amplification status and then mapped for 1p36 deletions. Horizontal bars indicate regions of loss (blue) or gain (red). (B) WB analysis demonstrating the different efficiency of the gRNAs designed to target ARID1A and CHD5. (C) FISH analysis illustrates the loss of internal clones (red probes) on NCCs that were transfected with our CRISPR/CAS9 constructs. (D) Karyotyping analysis shows a deletion on chromosome 4 (red arrow) of NCCs engineered through CRISPR/CAS9 technology.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4. In Vivo Tumor Studies (A) Diagram showing the different engineered NCC populations subcutaneously injected for tumor-onset studies. The Kaplan-Meier tumor-free survival curves show the different timing of tumor onset for different engineered NCCs. Tumor-free survival of mice injected with 1p36/Mycn NCCs was significantly shorter (p < 0.001) than that of mice injected with just Mycn -overexpressing cells. The log rank test was used to compare survival curves of two groups. (B) Immunohistochemically analysis of tumor differentiation markers. The tumors that developed after 1p36-del/ Mycn NCC injection showed increased expression of TUJ1 and S100 staining, whereas Mycn-alone-derived tumors showed an increase of glial cells. (C) Western blot analysis from protein extracts corresponding to Mycn and 1p36-del/ Mycn tumors presenting different tumor onset.
